BioventixBVNXF 62 Return-on-Tangible-Equity is 63.74% as of Dec. 2025, which is 9% above its 10-year median of 58.51. GuruFocus rates BVNXF with a GF Score™ of 62/100 and a GF Value™ of $32.94. The stock has 3 warning signs investors should review. Among 1,196 Biotechnology companies, Bioventix ranks better than 96.15% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bioventix's annualized net income for the quarter that ended in Dec. 2025 was $9.71 Mil. Bioventix's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $15.23 Mil. Therefore, Bioventix's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 63.74%.
The historical rank and industry rank for Bioventix's Return-on-Tangible-Equity or its related term are showing as below:
BVNXF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 47.24 Med: 58.51 Max: 70.1
Current: 65.87
During the past 13 years, Bioventix's highest Return-on-Tangible-Equity was 70.10%. The lowest was 47.24%. And the median was 58.51%.
BVNXF's Return-on-Tangible-Equity is ranked better than 96.15% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs BVNXF: 65.87
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bioventix Return-on-Tangible-Equity Related Terms
Bioventix Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bioventix's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BVNXF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Bioventix's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bioventix's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 63.74% mean?
Bioventix (BVNXF) has a Return-on-Tangible-Equity of 63.74% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioventix and its competitors. This is near median its historical median of 58.51. Over the past decade, Bioventix's Return-on-Tangible-Equity has ranged from 47.24 to 70.10. According to the industry distribution chart, Bioventix ranks #46 out of 1196 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Bioventix's Return-on-Tangible-Equity too high?
Bioventix's current Return-on-Tangible-Equity of 63.74% is near median its 10-year median of 58.51. Over the past 10 years, this metric has ranged from a low of 47.24 to a high of 70.10. Based on the distribution chart, Bioventix ranks #46 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #46 out of 1196 companies for Return-on-Tangible-Equity. This places Bioventix in the top 4% of its industry — outperforming the majority of peers. Historically, Bioventix's own Return-on-Tangible-Equity has ranged from 47.24 to 70.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioventix and its competitors. Bioventix's current Return-on-Tangible-Equity is 63.74%, which is near median its own 10-year median of 58.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Bioventix (BVNXF) has a current Return-on-Tangible-Equity of 63.74%. The stock's GF Value™ is $32.94, compared to a current price of $14.71 — trading 55.3% below its estimated fair value. The current Return-on-Tangible-Equity is 63.74%, which is near median its 10-year median of 58.51. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bioventix (BVNXF), the current Return-on-Tangible-Equity is 63.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (BVNXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of $14.71 is trading 55.3% below its estimated GF Value™ of $32.94.
Key valuation signals for BVNXF:
Return-on-Tangible-Equity: 63.74% (near median its 10-year median of 58.51)
GF Value™: $32.94 vs. price of $14.71 (55.3% below fair value)
No single metric tells the full story. See the BVNXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score
Get the complete analysis for BVNXF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVNXF has been successfully added to your 
